Galera Therapeutics Net Income

Galera Therapeutics (GRTX) currently reports a net income of $150M as of March 2026. That compares with $-16M in the prior-year period — up 1021.8% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Galera Therapeutics's net income history and peer comparisons.

Galera Therapeutics's net income increased from $-16M to $150M — a 1021.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Galera Therapeutics's net income of $150M is lower than the Healthcare sector average of $16B. That is roughly 99.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Galera Therapeutics reported $150M in net income as of March 2026. That compares with $-16M in the prior-year period — up 1021.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Galera Therapeutics, and consider following GRTX for alerts when major investors trade the stock.